The Pennsylvania State University (Penn State) was awarded a $384,063 Project Grant by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on the "Direct Genetic Modification of Plasmodium Sporozoites by mRNA/Lipid Nanoparticles." The two-year award, effective from February 1, 2025 to January 31, 2027, will enable Penn State to investigate transformative approaches to modifying the Plasmodium parasite, which causes malaria, using mRNA and lipid nanoparticle technologies. This research has the potential to support the development of novel malaria treatments and preventative measures that could benefit military service members and the broader public. As a highly capable research institution, Penn State regularly receives direct federal grants and serves as a subcontractor on grant-funded projects across health, defense, and other domains.
Generated 3/4/25, 5:19 AM